Dupilumab SAR231893 (REGN668)
Pre-clinicalRecruiting 0 watching 0 views this week💤 Quiet
22
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Prurigo Nodularis
Conditions
Prurigo Nodularis
Trial Timeline
Dec 27, 2023 → Dec 28, 2026
NCT ID
NCT06087627About Dupilumab SAR231893 (REGN668)
Dupilumab SAR231893 (REGN668) is a pre-clinical stage product being developed by Sanofi for Prurigo Nodularis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06087627. Target conditions include Prurigo Nodularis.
Hype Score Breakdown
Clinical
5
Activity
2
Company
9
Novelty
2
Community
1
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06087627 | Pre-clinical | Recruiting |
| NCT03992417 | Pre-clinical | Active |
| NCT03620747 | Phase 3 | Completed |
Competing Products
20 competing products in Prurigo Nodularis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Vixarelimab + Placebo | Kiniksa Pharmaceuticals | Phase 2 | 47 |
| Upadacitinib | AbbVie | Approved | 85 |
| Pimecrolimus + Hydrocortisone + Pimecrolimus | Novartis | Phase 2 | 52 |
| Rocatinlimab + Placebo | Amgen | Phase 3 | 76 |
| Abrocitinib | Pfizer | Phase 2 | 51 |
| Dupilumab | Sanofi | Phase 3 | 76 |
| Dupilumab | Sanofi | Pre-clinical | 22 |
| Dupilumab | Sanofi | Pre-clinical | 22 |
| Ruxolitinib Cream 1.5% | Incyte | Phase 1 | 30 |
| Ruxolitinib Cream + Vehicle Cream | Incyte | Phase 3 | 74 |
| INCB054707 + Placebo | Incyte | Phase 2 | 49 |
| Povorcitinib + Placebo | Incyte | Phase 3 | 74 |
| Povorcitinib + Placebo | Incyte | Phase 3 | 74 |
| Ruxolitinib Cream + Vehicle Cream | Incyte | Phase 3 | 74 |
| CDX-0159 + Normal saline | Celldex Therapeutics | Phase 1 | 28 |
| barzolvolimab | Celldex Therapeutics | Phase 2 | 47 |
| nalbuphine HCl ER tablets 90 mg BID + nalbuphine HCl ER tablets 180 mg BID + Placebo tablets BID | Trevi Therapeutics | Phase 2/3 | 60 |
| nalbuphine HCl ER | Trevi Therapeutics | Phase 2/3 | 60 |
| Nalbuphine ER Tablets + Placebo Tablets | Trevi Therapeutics | Phase 2/3 | 60 |
| serlopitant + Placebo | Vyne Therapeutics | Phase 2 | 44 |